Bill Taranto, who oversees Merck & Co’s Global Health Innovation Fund, talks to GCV’s James Mawson on the strategies of a sustainable CVC program.
Bill Taranto, who has been president of US-based pharmaceutical group Merck & Co’s corporate venture capital (CVC) fund since 2010, spoke with James Mawson, editor-in-chief of Global Corporate Venturing, on what longevity means for a CVC unit.
A GCV Powerlist mainstay who came in seventh last year, Taranto has been managing Merck & Co’s $500m evergreen fund called Global Health Innovation Fund (GHI) since its inception.
Echoing the words of this year’s Global Corporate Venturing & Innovation Summit co-chair,…
